Probiotics and Their Health Benefits

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Medical Microbiology".

Deadline for manuscript submissions: 31 August 2025 | Viewed by 686

Special Issue Editor


E-Mail Website
Guest Editor
College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, China
Interests: animal internal medicine and toxic diseases; animal nutritional metabolic diseases and immunity; intestinal microbes; probiotic fermentation; obesity; liver fibrosis; cholestatic liver injury
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Probiotics refer to live microorganisms, predominantly bacteria and yeast, that confer health benefits to the host when administered via oral or topical routes. Dysbiosis, characterized by an imbalance in pathogenic bacteria within the gut microbiome, has been implicated in inflammatory responses, metabolic disturbances, and malabsorption issues. Probiotics can enhance gut health by promoting the proliferation of beneficial microbiota, inhibiting the growth of pathogens, and maintaining gut homeostasis.

Research has demonstrated that probiotics possess therapeutic potential in managing various gastrointestinal disorders such as diarrhea, irritable bowel syndrome, ulcerative colitis, and Crohn’s disease. Their beneficial properties are associated with immunomodulatory mechanisms that reduce harmful bacteria and their toxic metabolites, including lipopolysaccharides (LPSS), while downregulating pro-inflammatory cytokines and upregulating the populations of mucus-producing bacteria like Akkermansia muciniphila.

Recent studies demonstrate the role of probiotics in metabolic health, particularly through the gut–liver axis, which links gut microbiota to lipid metabolism. This interaction has lowered cholesterol levels, mitigated weight gain, and improved insulin sensitivity. Although the precise mechanisms are still being elucidated, current findings support the potential of probiotics in fostering gastrointestinal, immunological, and metabolic health. However, further clinical trials are essential to clarify their therapeutic applications and optimize their use in clinical practice.

Dr. Yunhuan Liu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • probiotics
  • beneficial microbiota
  • host health
  • diseases

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

23 pages, 1454 KiB  
Systematic Review
Efficacy of Clostridium butyricum Supplementation Combined with Phototherapy for Neonatal Hyperbilirubinemia: A Systematic Review and Meta-Analysis
by Eun-Jin Kim, Ho-Yeon Go and Hyun-Kyung Sung
Microorganisms 2025, 13(7), 1441; https://doi.org/10.3390/microorganisms13071441 - 20 Jun 2025
Viewed by 522
Abstract
Neonatal hyperbilirubinemia (NH), which commonly presents as jaundice, affects approximately 60% of term infants and up to 80% of preterm infants within the first week of life. This study aimed to assess the efficacy and safety of Clostridium butyricum (C. butyricum) [...] Read more.
Neonatal hyperbilirubinemia (NH), which commonly presents as jaundice, affects approximately 60% of term infants and up to 80% of preterm infants within the first week of life. This study aimed to assess the efficacy and safety of Clostridium butyricum (C. butyricum) supplementation combined with phototherapy versus phototherapy alone for the treatment of NH. A systematic search of 11 databases (English, Chinese, and Korean) was conducted from 18 April 2025. Eligible randomized controlled trials (RCTs) compared C. butyricum plus phototherapy with phototherapy alone. Meta-analyses were performed using the mean difference (MD), standardized mean difference (SMD), and risk ratio (RR) with a 95% confidence interval (CIs). Evidence quality was evaluated using the GRADE approach. This review included 20 RCTs of 1054 neonates. Compared to phototherapy alone, C. butyricum supplementation significantly reduced total bilirubin (SMD = −1.54, 95% CI: −2.21 to −0.86), indirect bilirubin (SMD = −2.03, 95% CI: −2.98 to −1.07), and time to jaundice resolution (MD = −1.20 days, 95% CI: −1.66 to −0.75), and was associated with fewer adverse events (RR = 0.40, 95% CI: 0.30 to 0.55) (all p < 0.0001). These findings suggest that C. butyricum may have potential as a supportive adjunct therapy for neonatal hyperbilirubinemia. However, further studies are needed to confirm its efficacy and safety. The protocol is registered in PROSPERO (CRD420251031376). Full article
(This article belongs to the Special Issue Probiotics and Their Health Benefits)
Show Figures

Figure 1

Back to TopTop